These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 30690785

  • 21. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 22. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L, Vidal J, Carrasco JL, Muxi A, Portell E, Monegal A, Guañabens N, Peris P.
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.
    Tsourdi E, Makras P, Rachner TD, Polyzos S, Rauner M, Mandanas S, Hofbauer LC, Anastasilakis AD.
    Bone; 2019 Mar; 120():44-49. PubMed ID: 30292818
    [Abstract] [Full Text] [Related]

  • 25. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
    Hiramatsu R, Ubara Y, Sawa N, Sakai A.
    Nephrol Dial Transplant; 2021 Sep 27; 36(10):1900-1907. PubMed ID: 33544866
    [Abstract] [Full Text] [Related]

  • 26. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G.
    J Bone Miner Res; 2001 Nov 27; 16(11):2111-7. PubMed ID: 11697808
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. One versus 2 years of alendronate following denosumab: the CARD extension.
    Tsai JN, Jordan M, Lee H, Leder BZ.
    Osteoporos Int; 2024 Aug 07. PubMed ID: 39112628
    [Abstract] [Full Text] [Related]

  • 30. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
    Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H.
    J Nucl Med; 2009 Nov 07; 50(11):1808-14. PubMed ID: 19837766
    [Abstract] [Full Text] [Related]

  • 31. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul 07; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.
    Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N.
    Intern Med; 2017 Jul 07; 56(6):631-636. PubMed ID: 28321061
    [Abstract] [Full Text] [Related]

  • 34. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug 07; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study.
    Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N.
    J Bone Miner Metab; 2021 May 07; 39(3):463-473. PubMed ID: 33387064
    [Abstract] [Full Text] [Related]

  • 37. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients.
    Bonani M, Meyer U, Frey D, Graf N, Bischoff-Ferrari HA, Wüthrich RP.
    Kidney Blood Press Res; 2016 May 07; 41(5):614-622. PubMed ID: 27622692
    [Abstract] [Full Text] [Related]

  • 38. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group.
    Osteoporos Int; 2015 Mar 31; 26(3):1193-202. PubMed ID: 25592133
    [Abstract] [Full Text] [Related]

  • 40. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 31; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.